Decibel Therapeutics and Cocoon Biotech announced yesterday that the two companies plan to work together to research drug formulations optimized for transtympanic delivery to the ear.
The collaboration will make use of Cocoon’s silk fibroin platform and Decibel will have an option to exclusively license the technology on a program-by-program basis.
Get the full story at our sister site, Drug Delivery Business News.
